GÖKHAN GÖRGİŞEN, TAHİR ÇAKIR, CAN ATEŞ, İsmail Musab GÜLAÇAR, Zafer YAREN

Overexpression of Insulin Receptor Substrate 1 (IRS1) Promotes Radioresistance In A172 Glioblastoma Cell Line

Insulin receptor substrate 1 (IRS1) is the main adaptor molecule in insulin and insulin like growth factor signaling. Increased level of expression of IRS1 and IGF-1R proteins are associated with many human malignancies. They also induced resistance to therapeutic approaches such as chemo- and radiotherapy in cancer treatment however their molecular mechanisms are still unclear. Glioblastoma Multiforme (GBM) is the most common primary brain tumor in adults and radiotherapy has a pivotal role in its treatment. In this study, it is aimed to determine the relationship between IRS1 expression and radiosensitivity of GBM cells. Therefore, A172 cells transfected with pcDNA3.1-HA-tagged human IRS1 gene. Its overexpression was confirmed by western blot. IRS1 overexpressed A172 cells were irradiated with 5,8 and 10 Gray ionizing radiation and their effects on cell viability determined by MTT and clonogenic assay. Our results showed that overexpression of IRS1 led a decrease on sensitivity of the radiation in GBM cel ls. As a conclusion, this study should be confirmed by further molecular analysis and in vivo studies. IRS1 may be a predictive marker of radiosensitivity for GBM.

PDF

___

1. Coppola D, Ferber A, Miura M, et al. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol 1994; 14: 4588-4595.

2. Guevara-Aguirre J, Guevara A, Palacios I, Perez M, Procel P, Teran E. GH and GHR signaling in human disease. Growth Horm IGF Res 2018; 38: 34-38.

3. Valentinis B, Morrione A, Taylor SJ, Baserga R. Insulin-like growth factor I receptor signaling in transformation by src oncogenes. Mol Cell Biol 1997; 17: 3744-3754.

4. An Y, Cai Y, Guan Y, et al. Inhibitory effect of small interfering RNA targeting insulin-like growth factor-I receptor in ovarian cancer OVCAR3 cells. Cancer Biother Radiopharm 2010; 25: 545-552.

5. Christopoulos PF, Corthay A, Koutsilieris M. Aiming for the Insulin-like Growth Factor-1 system in breast cancer therapeutics. Cancer Treat Rev 2018; 63: 79-95.

6. Kaulfuss S, Burfeind P, Gaedcke J, Scharf JG. Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Mol Cancer Ther 2009; 8: 821-833.

7. Simpson A, Petnga W, Macaulay VM, WeyerCzernilofsky U, Bogenrieder T. Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies. Target Oncol 2017; 12: 571-597.

8. Amutha P, Rajkumar T. Role of Insulin-like Growth Factor, Insulin-like Growth Factor Receptors, and Insulin-like Growth Factorbinding Proteins in Ovarian Cancer. Indian J Med Paediatr Oncol 2017; 38: 198-206.

9. Gorgisen G, Gulacar IM, Ozes ON. The role of insulin receptor substrate (IRS) proteins in oncogenic transformation. Cell Mol Biol (Noisyle-grand) 2017; 63: 1-5.

10. Jagsi R. Progress and controversies: radiation therapy for invasive breast cancer. CA Cancer J Clin 2014; 64: 135-152.

11. Tang L, Wei F, Wu Y, et al. Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res 2018; 37: 87.

12. Cosaceanu D, Budiu RA, Carapancea M, Castro J, Lewensohn R, Dricu A. Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene 2007; 26: 2423-2434.

13. Qiu GH. Protection of the genome and central protein-coding sequences by non-coding DNA against DNA damage from radiation. Mutat Res Rev Mutat Res 2015; 764: 108-117.

14. Tezuka M, Watanabe H, Nakamura S, et al. Antiapoptotic activity is dispensable for insulinlike growth factor I receptor-mediated clonogenic radioresistance after gamma-irradiation. Clin Cancer Res 2001; 7: 3206-3214.

15. Bartucci M, Morelli C, Mauro L, Ando S, Surmacz E. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res 2001; 61: 6747-6754.

16. Li L, Qi X, Williams M, Shi Y, Keegan AD. Overexpression of insulin receptor substrate-1, but not insulin receptor substrate-2, protects a T cell hybridoma from activation-induced cell death. J Immunol 2002; 168: 6215-6223.

17. Lloret M, Lara PC, Bordon E, et al. IGF-1R expression in localized cervical carcinoma patients treated by radiochemotherapy. Gynecol Oncol 2007; 106: 8-11.

18. Turner BC, Haffty BG, Narayanan L, et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997; 57: 3079-3083.

19. Gupta K, Burns TC. Radiation-Induced Alterations in the Recurrent Glioblastoma Microenvironment: Therapeutic Implications. Front Oncol 2018; 8: 503.

20. Osuka S, Sampetrean O, Shimizu T, et al. IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells. Stem Cells 2013; 31: 627-640.

21. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928.

22. Li D, Chi G, Chen Z, Jin X. MicroRNA-1225-5p behaves as a tumor suppressor in human glioblastoma via targeting of IRS1. Onco Targets Ther. 2018; Sep 28; 11: 6339-6350.

23. Valenciano A, Henriquez-Hernandez LA, Moreno M, Lloret M, Lara PC. Role of IGF-1 receptor in radiation response. Transl Oncol 2012; 5: 1-9.

24. Kelley K, Knisely J, Symons M, Ruggieri R. Radioresistance of Brain Tumors. Cancers (Basel) 2016; 8(4).

25. Trojanek J, Ho T, Del Valle L, et al. Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. Mol Cell Biol 2003; 23: 7510-7524.

26. Mardilovich K, Pankratz SL, Shaw LM. Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal 2009; 7: 14.

27. de Sousa MML, Bjoras KO, Hanssen-Bauer A, Solvang-Garten K, Otterlei M. p38 MAPK signaling and phosphorylations in the BRCT1 domain regulate XRCC1 recruitment to sites of DNA damage. Sci Rep 2017; 7: 6322.

28. Guo F, Li J, Du W, et al. mTOR regulates DNA damage response through NF-kappaB-mediated FANCD2 pathway in hematopoietic cells. Leukemia 2013; 27: 2040-2046.

29. Jang NY, Kim DH, Cho BJ, et al. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer. BMC Cancer 2015; 15: 89.

30. Shen C, Oswald D, Phelps D, et al. Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA doublestrand breaks. Cancer Res 2013; 73: 3393-3401.

31. Fang J, Zhou SH, Fan J, Yan SX. Roles of glucose transporter-1 and the phosphatidylinositol 3kinase/protein kinase B pathway in cancer radioresistance (review). Mol Med Rep 2015; 11: 1573-1581.

32. De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, Nuyts S. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer 2005; 5: 42.

33. Kunkel M, Moergel M, Stockinger M, et al. Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. Oral Oncol 2007; 43: 796-803.